+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Anti-obesity Medication Market

  • PDF Icon

    Report

  • 200 Pages
  • May 2024
  • Region: Global
  • Erevna Healthcare
  • ID: 5968586
The global anti-obesity medication market accounted for USD 6.64 billion in 2023 and is expected to reach at USD 137.40 billion by 2034 with a CAGR of 31.71% during the forecast period 2024-2034. The market will grow as a result of factors such as the growing geriatric population, growing public awareness and concern about weight management, the rising prevalence of obesity and related chronic diseases, and strategic collaborations and partnerships.

The growing incidence of obesity globally is one of the main factors propelling the market for anti-obesity medications. Urbanization, bad eating patterns, and sedentary lifestyles are some of the factors that are contributing to the rising rate of obesity in all age categories. The market is growing as a result of the rising need for pharmaceutical therapies that help address obesity trends. For instance, Boehringer Ingelheim International GmbH announced in January 2024 the establishment of a new research alliance aimed at finding and creating innovative treatments for obesity and associated metabolic disorders.

By product, the approved product segment accounted for the highest revenue-grossing segment in the global anti-obesity medication market in 2023 and is predicted to grow at the fastest CAGR during the forecast period owing to the high efficacy, established safety profile, and widespread availability of approved anti-obesity medications, driving increased adoption and market penetration. For instance, Boehringer Ingelheim's decision to proceed with survodutide into Phase III trials in August 2023 indicates the increased interest in novel medicines. Phase II evidence demonstrating up to 19% weight loss highlights the potential efficacy of such drugs.

By the mechanism of action, the peripherally acting anti-obesity drugs segment accounted for the highest revenue-grossing segment in the global anti-obesity medication market in 2023 owing to the irreversible inhibition of pancreatic lipase, leading to reduced absorption of dietary fats and enhanced weight loss outcomes, thereby driving significant revenue growth in the segment. For instance, Vivus, Inc. announced in October 2023 that it would be working with a new partner to develop and market Qsymia (phentermine/topiramate) in a particular area. Additionally, the centrally acting drugs segment is predicted to grow at the fastest CAGR during the forecast period owing to the increased understanding of the central nervous system's role in regulating appetite and metabolism, leading to the development of novel centrally acting drugs with improved efficacy and safety profiles, driving robust growth in the segment.

By distribution channel, the retail pharmacies segment accounted for the highest revenue-grossing segment in the global anti-obesity medication market in 2023 owing to the convenience, accessibility, and wide distribution network of retail pharmacies, catering to the growing demand for anti-obesity medications among consumers seeking over-the-counter and prescription options. For instance, in December 2023, Roche announced the acquisition of Carmot Therapeutics for USD 2.7 billion plus up to USD 400 million in milestones, acquiring access to clinical-stage obesity treatments, including lead asset CT-388, which targets obesity and related illnesses. Additionally, the online pharmacies segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing preference for online shopping, the convenience of home delivery, and expanding digital infrastructure, facilitating easy access to a wide range of anti-obesity medications and driving significant growth in the segment.

North American region is anticipated to have the highest revenue share during the forecast period owing to the high prevalence of obesity, well-established healthcare infrastructure, increasing adoption of anti-obesity medications, and robust research and development activities, driving substantial revenue growth in the North American region. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rising awareness about obesity-related health risks, improving healthcare infrastructure, increasing disposable incomes, and growing prevalence of obesity in emerging economies, driving significant market expansion in the Asia Pacific region. For instance, Novo Nordisk's November 2023 investment in expanding production facilities in Chartres, France, demonstrates confidence in the market's potential. The investment, which exceeds USD 2.32 billion, would increase capacity for chronic disease treatments, including anti-obesity drugs.

This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.

Report Scope:

  • Base Year: 2023
  • Forecast Period: 2024-2034
  • Study Coverage
  • Market Forecast by Product, Mechanism of Action, and Distribution Channel
  • Market Forecast for 5 Regions and 17+ Countries
  • North America (U.S. and Canada)
  • Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
  • Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
  • Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
  • MEA (South Africa, GCC, Rest of MEA)
  • Exhaustive Company Profiles of the Top 10+ Major Market Players
  • 20% Free Customization Available to Meet Your Exact Requirement. Click here for more details

Segmentation: Anti-obesity Medication Market Report 2023 - 2034

Anti-obesity Medication Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)

  • Approved
  • Bupropion-naltrexone (Contrave)
  • Liraglutide (Orlistat)
  • Orlistat
  • Phentermine-topiramate (Qsymia)
  • Semaglutide (Wegovy)
  • Setmelanotide (Imcivree)
  • Tirzepatide (Zepbound)
  • Off Label
  • Semaglutide (Xenical Alli)
  • Liraglutide (Semaglutide (Wegovy))
  • Dulaglutide (Trulicity)
  • Topiramate (Dulaglutide (Trulicity))
  • Others

Anti-obesity Medication Market Analysis & Forecast by Mechanism of Action 2023 - 2034 (Revenue USD Bn)

  • Peripherally Acting Drugs
  • Centrally Acting Drugs

Anti-obesity Medication Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Anti-obesity Medication Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)· North America

  • U.S.
  • Canada
  • Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM
  • Middle East & Africa
  • South Africa
  • GCC
  • Rest of MEA

Table of Contents

1. Research Methodology
1.1. Study Objectives
1.2. Study Scope
1.3. Research Assumptions
1.4. Research Framework
2. Introduction
2.1. Market Definition
2.2. Global Anti-obesity Medication Market Overview
3. Executive Summary
4. Market Environment Analysis
4.1. Porter’s 5 Forces Analysis
4.2. PESTEL Analysis
4.3. SWOT Analysis
5. Market Dynamics
5.1. Drivers Analysis
5.2. Restraints Analysis
5.3. Opportunities Analysis
5.4. Threats Analysis
5.5. Trend Analysis
6. COVID-19 Impact Analysis
7. Anti-obesity Medication Market: Product Estimates & Trend Analysis
7.1. Product Segment Opportunity Analysis
7.2. Approved
7.2.1. Approved Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
7.2.1.1. Bupropion-naltrexone (Contrave)
7.2.1.1.1. Bupropion-naltrexone (Contrave) Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
7.2.1.2. Liraglutide (Orlistat)
7.2.1.2.1. Liraglutide (Orlistat) Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
7.2.1.3. Orlistat
7.2.1.3.1. Orlistat Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
7.2.1.4. Phentermine-topiramate (Qsymia)
7.2.1.4.1. Phentermine-topiramate (Qsymia) Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
7.2.1.5. Semaglutide (Wegovy)
7.2.1.5.1. Semaglutide (Wegovy) Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
7.2.1.6. Setmelanotide (Imcivree)
7.2.1.6.1. Setmelanotide (Imcivree) Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
7.2.1.7. Tirzepatide (Zepbound)
7.2.1.7.1. Tirzepatide (Zepbound) Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
7.3. Off Label
7.3.1. Off-Label Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
7.3.1.1. Semaglutide (Xenical Alli)
7.3.1.1.1. Semaglutide (Xenical Alli) Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
7.3.1.2. Liraglutide (Semaglutide (Wegovy))
7.3.1.2.1. Liraglutide (Semaglutide (Wegovy)) Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
7.3.1.3. Dulaglutide (Trulicity)
7.3.1.3.1. Dulaglutide (Trulicity) Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
7.3.1.4. Topiramate (Dulaglutide (Trulicity))
7.3.1.4.1. Topiramate (Dulaglutide (Trulicity)) Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
7.3.1.5. Others
7.3.1.5.1. Others Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
8. Anti-obesity Medication Market: Mechanism of Action Estimates & Trend Analysis
8.1. Mechanism of Action Segment Opportunity Analysis
8.2. Peripherally Acting Drugs
8.2.1. Peripherally Acting Drugs Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
8.3. Centrally Acting Drugs
8.3.1. Centrally Acting Drugs Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
9. Anti-obesity Medication Market: Distribution Channel Estimates & Trend Analysis
9.1. Distribution Channel Segment Opportunity Analysis
9.2. Hospital Pharmacies
9.2.1. Hospital Pharmacies Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
9.3. Retail Pharmacies
9.3.1. Retail Pharmacies Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
9.4. Online Pharmacies
9.4.1. Online Pharmacies Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
10. Regional Market Analysis
10.1. Regional Market Opportunity Analysis
11. North America Anti-obesity Medication Market
11.1. North America Anti-obesity Medication Market
11.1.1. North America Anti-obesity Medication Market Size and Forecast, 2023-2034 (Revenue USD Bn)
11.1.2. North America Anti-obesity Medication Market Size and Forecast, By Country, 2023-2034 (Revenue USD Bn)
11.1.3. North America Anti-obesity Medication Market Size and Forecast, By Product, 2023-2034 (Revenue USD Bn)
11.1.4. North America Anti-obesity Medication Market Size and Forecast, By Mechanism of Action, 2023-2034 (Revenue USD Bn)
11.1.5. North America Anti-obesity Medication Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
11.2. U.S. Global Anti-obesity Medication Market
11.2.1. U.S. Anti-obesity Medication Market Size and Forecast, 2023-2034 (Revenue USD Bn)
11.2.2. U.S. Anti-obesity Medication Market Size and Forecast, By Product, 2023-2034 (Revenue USD Bn)
11.2.3. U.S. Anti-obesity Medication Market Size and Forecast, By Mechanism of Action, 2023-2034 (Revenue USD Bn)
11.2.4. U.S. Anti-obesity Medication Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
11.3. Canada Global Anti-obesity Medication Market
11.3.1. Canada Anti-obesity Medication Market Size and Forecast, 2023-2034 (Revenue USD Bn)
11.3.2. Canada Anti-obesity Medication Market Size and Forecast, By Product, 2023-2034 (Revenue USD Bn)
11.3.3. Canada Anti-obesity Medication Market Size and Forecast, By Mechanism of Action, 2023-2034 (Revenue USD Bn)
11.3.4. Canada Anti-obesity Medication Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
12. Europe Global Anti-obesity Medication Market
12.1. Europe Global Anti-obesity Medication Market
12.1.1. Europe Anti-obesity Medication Market Size and Forecast, 2023-2034 (Revenue USD Bn)
12.1.2. Europe Anti-obesity Medication Market Size and Forecast, By Country, 2023-2034 (Revenue USD Bn)
12.1.3. Europe Anti-obesity Medication Market Size and Forecast, By Product, 2023-2034 (Revenue USD Bn)
12.1.4. Europe Anti-obesity Medication Market Size and Forecast, By Mechanism of Action, 2023-2034 (Revenue USD Bn)
12.1.5. Europe Anti-obesity Medication Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
12.2. Germany Global Anti-obesity Medication Market
12.2.1. Germany Anti-obesity Medication Market Size and Forecast, 2023-2034 (Revenue USD Bn)
12.2.2. Germany Anti-obesity Medication Market Size and Forecast, By Product, 2023-2034 (Revenue USD Bn)
12.2.3. Germany Anti-obesity Medication Market Size and Forecast, By Mechanism of Action, 2023-2034 (Revenue USD Bn)
12.2.4. Germany Anti-obesity Medication Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
12.3. UK Global Anti-obesity Medication Market
12.3.1. UK Anti-obesity Medication Market Size and Forecast, 2023-2034 (Revenue USD Bn)
12.3.2. UK Anti-obesity Medication Market Size and Forecast, By Product, 2023-2034 (Revenue USD Bn)
12.3.3. UK Anti-obesity Medication Market Size and Forecast, By Mechanism of Action, 2023-2034 (Revenue USD Bn)
12.3.4. UK Anti-obesity Medication Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
12.4. France Global Anti-obesity Medication Market
12.4.1. France Anti-obesity Medication Market Size and Forecast, 2023-2034 (Revenue USD Bn)
12.4.2. France Anti-obesity Medication Market Size and Forecast, By Product, 2023-2034 (Revenue USD Bn)
12.4.3. France Anti-obesity Medication Market Size and Forecast, By Mechanism of Action, 2023-2034 (Revenue USD Bn)
12.4.4. France Anti-obesity Medication Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
12.5. Spain Global Anti-obesity Medication Market
12.5.1. Spain Anti-obesity Medication Market Size and Forecast, 2023-2034 (Revenue USD Bn)
12.5.2. Spain Anti-obesity Medication Market Size and Forecast, By Product, 2023-2034 (Revenue USD Bn)
12.5.3. Spain Anti-obesity Medication Market Size and Forecast, By Mechanism of Action, 2023-2034 (Revenue USD Bn)
12.5.4. Spain Anti-obesity Medication Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
12.6. Italy Global Anti-obesity Medication Market
12.6.1. Italy Anti-obesity Medication Market Size and Forecast, 2023-2034 (Revenue USD Bn)
12.6.2. Italy Anti-obesity Medication Market Size and Forecast, By Product, 2023-2034 (Revenue USD Bn)
12.6.3. Italy Anti-obesity Medication Market Size and Forecast, By Mechanism of Action, 2023-2034 (Revenue USD Bn)
12.6.4. Italy Anti-obesity Medication Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
12.7. Rest of Europe Global Anti-obesity Medication Market
12.7.1. Rest of Europe Anti-obesity Medication Market Size and Forecast, 2023-2034 (Revenue USD Bn)
12.7.2. Rest of Europe Anti-obesity Medication Market Size and Forecast, By Product, 2023-2034 (Revenue USD Bn)
12.7.3. Rest of Europe Anti-obesity Medication Market Size and Forecast, By Mechanism of Action, 2023-2034 (Revenue USD Bn)
12.7.4. Rest of Europe Anti-obesity Medication Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
13. Asia Pacific Global Anti-obesity Medication Market
13.1. Asia Pacific Global Anti-obesity Medication Market
13.1.1. Asia Pacific Anti-obesity Medication Market Size and Forecast, 2023-2034 (Revenue USD Bn)
13.1.2. Asia Pacific Anti-obesity Medication Market Size and Forecast, By Country, 2023-2034 (Revenue USD Bn)
13.1.3. Asia Pacific Anti-obesity Medication Market Size and Forecast, By Product, 2023-2034 (Revenue USD Bn)
13.1.4. Asia Pacific Anti-obesity Medication Market Size and Forecast, By Mechanism of Action, 2023-2034 (Revenue USD Bn)
13.1.5. Asia Pacific Anti-obesity Medication Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
13.2. Japan Global Anti-obesity Medication Market
13.2.1. Japan Anti-obesity Medication Market Size and Forecast, 2023-2034 (Revenue USD Bn)
13.2.2. Japan Anti-obesity Medication Market Size and Forecast, By Product, 2023-2034 (Revenue USD Bn)
13.2.3. Japan Anti-obesity Medication Market Size and Forecast, By Mechanism of Action, 2023-2034 (Revenue USD Bn)
13.2.4. Japan Anti-obesity Medication Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
13.3. China Global Anti-obesity Medication Market
13.3.1. China Anti-obesity Medication Market Size and Forecast, 2023-2034 (Revenue USD Bn)
13.3.2. China Anti-obesity Medication Market Size and Forecast, By Product, 2023-2034 (Revenue USD Bn)
13.3.3. China Anti-obesity Medication Market Size and Forecast, By Mechanism of Action, 2023-2034 (Revenue USD Bn)
13.3.4. China Anti-obesity Medication Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
13.4. India Global Anti-obesity Medication Market
13.4.1. India Anti-obesity Medication Market Size and Forecast, 2023-2034 (Revenue USD Bn)
13.4.2. India Anti-obesity Medication Market Size and Forecast, By Product, 2023-2034 (Revenue USD Bn)
13.4.3. India Anti-obesity Medication Market Size and Forecast, By Mechanism of Action, 2023-2034 (Revenue USD Bn)
13.4.4. India Anti-obesity Medication Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
13.5. South Korea Global Anti-obesity Medication Market
13.5.1. South Korea Anti-obesity Medication Market Size and Forecast, 2023-2034 (Revenue USD Bn)
13.5.2. South Korea Anti-obesity Medication Market Size and Forecast, By Product, 2023-2034 (Revenue USD Bn)
13.5.3. South Korea Anti-obesity Medication Market Size and Forecast, By Mechanism of Action, 2023-2034 (Revenue USD Bn)
13.5.4. South Korea Anti-obesity Medication Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
13.6. Australia Global Anti-obesity Medication Market
13.6.1. Australia Anti-obesity Medication Market Size and Forecast, 2023-2034 (Revenue USD Bn)
13.6.2. Australia Anti-obesity Medication Market Size and Forecast, By Product, 2023-2034 (Revenue USD Bn)
13.6.3. Australia Anti-obesity Medication Market Size and Forecast, By Mechanism of Action, 2023-2034 (Revenue USD Bn)
13.6.4. Australia Anti-obesity Medication Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
13.7. Rest of Asia Pacific Global Anti-obesity Medication Market
13.7.1. Rest of Asia Pacific Anti-obesity Medication Market Size and Forecast, 2023-2034 (Revenue USD Bn)
13.7.2. Rest of Asia Pacific Anti-obesity Medication Market Size and Forecast, By Product, 2023-2034 (Revenue USD Bn)
13.7.3. Rest of Asia Pacific Anti-obesity Medication Market Size and Forecast, By Mechanism of Action, 2023-2034 (Revenue USD Bn)
13.7.4. Rest of Asia Pacific Anti-obesity Medication Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
14. Latin America Global Anti-obesity Medication Market
14.1. Latin America Global Anti-obesity Medication Market
14.1.1. Latin America Anti-obesity Medication Market Size and Forecast, 2023-2034 (Revenue USD Bn)
14.1.2. Latin America Anti-obesity Medication Market Size and Forecast, By Country, 2023-2034 (Revenue USD Bn)
14.1.3. Latin America Anti-obesity Medication Market Size and Forecast, By Product, 2023-2034 (Revenue USD Bn)
14.1.4. Latin America Anti-obesity Medication Market Size and Forecast, By Mechanism of Action, 2023-2034 (Revenue USD Bn)
14.1.5. Latin America Anti-obesity Medication Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
14.2. Brazil Global Anti-obesity Medication Market
14.2.1. Brazil Anti-obesity Medication Market Size and Forecast, 2023-2034 (Revenue USD Bn)
14.2.2. Brazil Anti-obesity Medication Market Size and Forecast, By Product, 2023-2034 (Revenue USD Bn)
14.2.3. Brazil Anti-obesity Medication Market Size and Forecast, By Mechanism of Action, 2023-2034 (Revenue USD Bn)
14.2.4. Brazil Anti-obesity Medication Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
14.3. Mexico Global Anti-obesity Medication Market
14.3.1. Mexico Anti-obesity Medication Market Size and Forecast, 2023-2034 (Revenue USD Bn)
14.3.2. Mexico Anti-obesity Medication Market Size and Forecast, By Product, 2023-2034 (Revenue USD Bn)
14.3.3. Mexico Anti-obesity Medication Market Size and Forecast, By Mechanism of Action, 2023-2034 (Revenue USD Bn)
14.3.4. Mexico Anti-obesity Medication Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
14.4. Argentina Global Anti-obesity Medication Market
14.4.1. Argentina Anti-obesity Medication Market Size and Forecast, 2023-2034 (Revenue USD Bn)
14.4.2. Argentina Anti-obesity Medication Market Size and Forecast, By Product, 2023-2034 (Revenue USD Bn)
14.4.3. Argentina Anti-obesity Medication Market Size and Forecast, By Mechanism of Action, 2023-2034 (Revenue USD Bn)
14.4.4. Argentina Anti-obesity Medication Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
14.5. Rest of Latin America Global Anti-obesity Medication Market
14.5.1. Rest of Latin America Anti-obesity Medication Market Size and Forecast, 2023-2034 (Revenue USD Bn)
14.5.2. Rest of Latin America Anti-obesity Medication Market Size and Forecast, By Product, 2023-2034 (Revenue USD Bn)
14.5.3. Rest of Latin America Anti-obesity Medication Market Size and Forecast, By Mechanism of Action, 2023-2034 (Revenue USD Bn)
14.5.4. Rest of Latin America Anti-obesity Medication Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
15. MEA Global Anti-obesity Medication Market
15.1. MEA Global Anti-obesity Medication Market
15.1.1. MEA Anti-obesity Medication Market Size and Forecast, 2023-2034 (Revenue USD Bn)
15.1.2. MEA Anti-obesity Medication Market Size and Forecast, By Country, 2023-2034 (Revenue USD Bn)
15.1.3. MEA Anti-obesity Medication Market Size and Forecast, By Product, 2023-2034 (Revenue USD Bn)
15.1.4. MEA Anti-obesity Medication Market Size and Forecast, By Mechanism of Action, 2023-2034 (Revenue USD Bn)
15.1.5. MEA Anti-obesity Medication Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
15.2. GCC Global Anti-obesity Medication Market
15.2.1. GCC Anti-obesity Medication Market Size and Forecast, 2023-2034 (Revenue USD Bn)
15.2.2. GCC Anti-obesity Medication Market Size and Forecast, By Product, 2023-2034 (Revenue USD Bn)
15.2.3. GCC Anti-obesity Medication Market Size and Forecast, By Mechanism of Action, 2023-2034 (Revenue USD Bn)
15.2.4. GCC Anti-obesity Medication Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
15.3. South Africa Global Anti-obesity Medication Market
15.3.1. South Africa Anti-obesity Medication Market Size and Forecast, 2023-2034 (Revenue USD Bn)
15.3.2. South Africa Anti-obesity Medication Market Size and Forecast, By Product, 2023-2034 (Revenue USD Bn)
15.3.3. South Africa Anti-obesity Medication Market Size and Forecast, By Mechanism of Action, 2023-2034 (Revenue USD Bn)
15.3.4. South Africa Anti-obesity Medication Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
15.4. Rest of MEA Global Anti-obesity Medication Market
15.4.1. Rest of MEA Anti-obesity Medication Market Size and Forecast, 2023-2034 (Revenue USD Bn)
15.4.2. Rest of MEA Anti-obesity Medication Market Size and Forecast, By Product, 2023-2034 (Revenue USD Bn)
15.4.3. Rest of MEA Anti-obesity Medication Market Size and Forecast, By Mechanism of Action, 2023-2034 (Revenue USD Bn)
15.4.4. Rest of MEA Anti-obesity Medication Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
16. Competitor Analysis
16.1. Company Market Share Analysis, 2023
16.2. Major Recent Developments
17. Company Profiles
17.1. Novo Nordisk A/S
17.2. Eisai Co., Ltd.
17.3. Vivus, Inc.
17.4. Arena Pharmaceuticals, Inc.
17.5. Orexigen Therapeutics, Inc.
17.6. Nalpropion Pharmaceuticals, Inc.
17.7. Boehringer Ingelheim International GmbH
17.8. Takeda Pharmaceutical Company Limited
17.9. GlaxoSmithKline plc
17.10. F. Hoffmann-La Roche Ltd
17.11. Amgen Inc.
17.12. Sanofi S.A.
17.13. Pfizer Inc.
17.14. Merck & Co., Inc.
17.15. Johnson & Johnson Services, Inc.
18. Conclusion19. Recommendations

Companies Mentioned

  • Novo Nordisk A/S
  • Eisai Co. Ltd.
  • Vivus Inc.
  • Arena Pharmaceuticals Inc.
  • Orexigen Therapeutics Inc.
  • Nalpropion Pharmaceuticals Inc.
  • Boehringer Ingelheim International GmbH
  • Takeda Pharmaceutical Company Limited
  • GlaxoSmithKline plc
  • F. Hoffmann-La Roche Ltd
  • Amgen Inc.
  • Sanofi S.A.
  • Pfizer Inc.
  • Merck & Co. Inc.
  • Johnson & Johnson Services Inc.